QuarryBio (formerly ReclaimRx) characterizes α-synuclein for Parkinson’s disease research for Michael J Fox Foundation

Home/News/QuarryBio (formerly ReclaimRx) characterizes α-synuclein for Parkinson’s disease research for Michael J Fox Foundation

QuarryBio (formerly ReclaimRx) characterizes α-synuclein for Parkinson’s disease research for Michael J Fox Foundation

QuarryBio (formerly named ReclaimRx) is pleased to announce the successful completion of a quality assurance project performed for The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to evaluate the quality and identity of semi-synthetic α-synuclein supplied for Parkinson’s disease research.

α-synuclein is thought to play a significant role in the onset and progression of Parkinson’s disease.  To support disease research, MJFF requested that QuarryBio perform an evaluation of a new, semi-synthetic supply of α-synuclein.  Using its in-house mass spectrometer, QuarryBio confirmed the identity and purity of the sample, providing the confirmation needed to allow MJFF to move forward with its α-synuclein research plans.

“We were pleased to successfully complete quality assurance testing of α-synuclein, and to support MJFF efforts to understand and cure Parkinson’s disease,” said Eric Graban, CEO of QuarryBio. “Our data clearly confirmed the identity and purity of α-synuclein, enabling MJFF to move forward with its research agenda.”

α-synuclein is an important target for candidate drugs that may slow or stop the progression of Parkinson’s disease,” said Terina Martinez, PhD, MJFF associate director of research programs. “We’re grateful to QuarryBio for its important work in confirming the quality of an important new supply of α-synuclein.”

By | 2017-02-02T19:08:50+00:00 July 31st, 2012|News|0 Comments

About the Author:

Leave A Comment